Metabolism of styrene in the human liver in vitro:: interindividual variation and enantioselectivity

被引:17
作者
Wenker, MAM
Kezic, S
Monster, AC
De Wolff, FA
机构
[1] Univ Amsterdam, Acad Med Ctr, Coronel Inst, NL-1100 DE Amsterdam, Netherlands
[2] Leiden Univ, Med Ctr, Toxicol Lab, Leiden, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Chair Human Toxicol, Res Inst Neurosci Amsterdam, NL-1012 WX Amsterdam, Netherlands
关键词
D O I
10.1080/00498250010031638
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. The interindividual variation and enantioselectivity of the in vitro styrene oxidation by cytochrome P450 have been investigated in 20 human microsomal liver samples. Liver samples were genotyped for the CYP2E1*6 and CYP2E1*5B alleles. 2. Kinetic analysis indicated the presence of at least two forms of styrene-metabolizing cytochrome P450. The enzyme constants for the high-affinity component were subject to appreciable interindividual variation, i.e. V-max1 ranged from 0.39 to 3.20 nmol mg protein(-1) min(-1) (0.96 +/- 0.63) and K-m1 ranged from 0.005 to 0. 03 mM (0.011 +/- 0.006). Inhibition studies with chemical inhibitors of CYP2E1, CYP1A2, CYP2C8/9 and CYP3A4 demonstrated that CYP2E1 was the primary enzyme involved in the high-affinity component of styrene oxidation. No relationship between the interindividual variation in V-max1 and K-m1 and the genetic polymorphisms of the CYP2E1 gene was found. 3. Cytochrome P450-mediated oxidation of styrene demonstrated a moderate enantioselectivity, with an enantiomeric excess (ee) of (S)-styrene oxide of 15% (range 4-27%) at low styrene concentration and an ee of (R)-styrene oxide of 7% (range -11 to +22%) at high styrene concentration. This points towards the involvement of at least two cytochrome P450, with different enantioselectivities. 4. The data indicate that cytochrome P450-mediated styrene oxidation is subject to considerable interindividual variation, but only to a moderate product enantioselectivity.
引用
收藏
页码:61 / 72
页数:12
相关论文
共 42 条
[1]  
ARLIENSOBORG P, 1992, SOLVENT NEUROTOXICIT, P129
[2]   THE GENETIC TOXICOLOGY OF STYRENE AND STYRENE OXIDE [J].
BARALE, R .
MUTATION RESEARCH, 1991, 257 (02) :107-126
[3]   ENANTIOSELECTIVITY IN THE RABBIT LIVER MICROSOMAL BIOTRANSFORMATION OF STYRENE AND PHENYLPROPENES [J].
BELLUCCI, G ;
CHIAPPE, C ;
CORDONI, A ;
MARIONI, F .
BIOCATALYSIS, 1994, 10 (1-4) :149-157
[4]   REVIEW OF THE TOXICOLOGY OF STYRENE [J].
BOND, JA .
CRC CRITICAL REVIEWS IN TOXICOLOGY, 1989, 19 (03) :227-249
[5]   Human cytochrome P450 2E1 (CYP2E1): From genotype to phenotype [J].
Carriere, V ;
Berthou, F ;
Baird, S ;
Belloc, C ;
Beaune, P ;
deWaziers, I .
PHARMACOGENETICS, 1996, 6 (03) :203-211
[6]   EVALUATION OF TRIACETYLOLEANDOMYCIN, ALPHA-NAPHTHOFLAVONE AND DIETHYLDITHIOCARBAMATE AS SELECTIVE CHEMICAL PROBES FOR INHIBITION OF HUMAN CYTOCHROMES P450 [J].
CHANG, TKH ;
GONZALEZ, FJ ;
WAXMAN, DJ .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1994, 311 (02) :437-442
[7]  
CHERRY N, 1990, BRIT J IND MED, V47, P29
[8]   Stereochemistry of the biotransformation of 1-hexene and 2-methyl-1-hexene with rat liver microsomes and purified P450s of rats and humans [J].
Chiappe, C ;
De Rubertis, A ;
Amato, G ;
Gervasi, PG .
CHEMICAL RESEARCH IN TOXICOLOGY, 1998, 11 (12) :1487-1493
[9]   In vitro assessment of human cytochrome P450 [J].
Clarke, SE .
XENOBIOTICA, 1998, 28 (12) :1167-1202
[10]  
FOUREMAN GL, 1989, J PHARMACOL EXP THER, V248, P492